Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis--implications for chemoprevention.
Gastric adenocarcinoma is the second most common cause of cancer-related mortality worldwide. Infection with Helicobacter pylori is the single most common cause of adenocarcinoma of the distal stomach. Cancer risk is believed to be related to differences among H. pylori strains and inflammatory responses governed by host genetics. In particular, specific interactions between host factors that modulate the response to the infection, and bacterial virulence factors that can directly cause tissue damage seem to have a major pathogenic role in the development of gastric cancer. In addition, environmental factors can modify key growth signaling pathways within the gastric mucosa, which leads to the alteration of epithelial cell growth. Preventive strategies represent the most promising means of decreasing cancer risk, and must be aimed at the control of H. pylori infection, improvement of environmental conditions, and the identification of subjects who are genetically predisposed to the development of cancer in response to H. pylori infection. Understanding the intracellular signaling pathways that are specifically affected by H. pylori and that promote phenotypic and genotypic changes that might ultimately progress to malignant transformation could enable physicians to focus eradication therapy appropriately and design interventions targeted at the molecular level to prevent the development of gastric cancer.
Romano
Marco
M
Dipartimento di Internistica Clinica e Sperimentale A Lanzara e F Magrassi--Gastroenterologia e CIRANAD, Seconda Università di Napoli, II Policlinico, Ed 3, Secondo piano, Via Pansini 5, 80131 Napoli, Italy. marco.romano@unina2.it
Ricci
Vittorio
V
Zarrilli
Raffaele
R
D000975:Antioxidants / Q000494:pharmacology; D018899:CpG Islands; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D019587:Dietary Supplements; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori / Q000235:genetics / Q000472:pathogenicity; D006801:Humans; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000517:prevention & control*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
D000975:Antioxidants; D052246:Cyclooxygenase 2 Inhibitors; D066246:ErbB Receptors; D040301:Vascular Endothelial Growth Factor Receptor-2